Get started
Author

Ulrika Emerath

Observed name: Emerath U
Observed institution: AstraZeneca (Sweden)
OpenAlex ID: A5030120194
Safety of As-Needed Budesonide-Formoterol in Mild Asthma: Data from the Two Phase III SYGMA Studies
2021 · J. Mark FitzGerald, Paul M. O’Byrne, et al. · Drug Safety · 19
PDF
MELTEMI and COLUMBA: 5-Year Comparative Safety Analysis of Benralizumab and Mepolizumab
2024 · Arnaud Bourdin, Geoffrey Chupp, et al. · The Journal of Allergy and Clinical Immunology In Practice · 14
The risk of hyperkalemia in COPD and asthma patients
2019 · Jukka Mäenpää, Ulrika Emerath, et al. · 2
Hyperkalemia Is an Underestimated Risk Factor in COPD
2025 · Jukka Mäenpää, Isobel Anderson, et al. · International Journal of COPD · 1
PDF
Incidence of New Malignancies in Severe Asthma: Comparison of Real-World Patients Treated with Benralizumab, Other Biologics, or Non-biologics
2026 · Eileen O. Dareng, Trung N. Tran, et al. · Pulmonary Therapy
PDF
Hyperkalemia is an underestimated risk factor in COPD: a retrospective study from two Phase 3 trials
2023 · Jukka Mäenpää, Isobel Anderson, et al.
Works count: 7
Citation count: 36
H-index: 2
I10-index: 2
Year
Topic
Type